BR112015029530A8 - métodos para tratamento de condições inflamatórias utilizando s-[4-(3-fluoro-3-metilbutiriloxi)but-2-inil] 6\alpha, 9\alpha-difluoro-17\alpha-(furan-2-il)carboniloxi-11\beta-hidroxi-16\alpha-metil-3-oxoandrosta-1, 4-dieno-17\beta-carbotioato. - Google Patents

métodos para tratamento de condições inflamatórias utilizando s-[4-(3-fluoro-3-metilbutiriloxi)but-2-inil] 6\alpha, 9\alpha-difluoro-17\alpha-(furan-2-il)carboniloxi-11\beta-hidroxi-16\alpha-metil-3-oxoandrosta-1, 4-dieno-17\beta-carbotioato. Download PDF

Info

Publication number
BR112015029530A8
BR112015029530A8 BR112015029530A BR112015029530A BR112015029530A8 BR 112015029530 A8 BR112015029530 A8 BR 112015029530A8 BR 112015029530 A BR112015029530 A BR 112015029530A BR 112015029530 A BR112015029530 A BR 112015029530A BR 112015029530 A8 BR112015029530 A8 BR 112015029530A8
Authority
BR
Brazil
Prior art keywords
alpha
oxoandrosta
methylbutyryloxy
carbothioate
carbonyloxy
Prior art date
Application number
BR112015029530A
Other languages
English (en)
Other versions
BR112015029530A2 (pt
Inventor
Trinadha Rao Chitturi
Sanjivkumar Sheth Gaurav
Chimanlal Patel Gopalkumar
Ranchhodbhai Patel Jiten
Thennati Rajamannar
Nandlal Mandhane Sanjay
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of BR112015029530A2 publication Critical patent/BR112015029530A2/pt
Publication of BR112015029530A8 publication Critical patent/BR112015029530A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

métodos para o tratamento de condições inflamatórias utilizando s-(4-(3-fluoro-3-metilbutiriloxi)but-2-inil]6 a,9a- difluoro-17a-(furan-2-il)carboniloxi-11fá-hidroxi-16 a-metil-3- oxoandrosta-1,4-dieno-17fi-carbotioato. a presente invenção refere-se a métodos de tratamento de condições inflamatórias utilizando s-[4-(3-fluoro-3- metilbutiriloxi)-but-2-inil]6a,9a-difluoro-17a-(furan-2-il) carboniloxi-llp-hidroxi-16a-metil-3-oxoandrosta-1,4-dieno-17f3.- carbotioato (composto de fórmula i), um novo composto anti- inflamatório da série dos androstanos e a seus processos de preparação.
BR112015029530A 2013-05-28 2014-05-28 métodos para tratamento de condições inflamatórias utilizando s-[4-(3-fluoro-3-metilbutiriloxi)but-2-inil] 6\alpha, 9\alpha-difluoro-17\alpha-(furan-2-il)carboniloxi-11\beta-hidroxi-16\alpha-metil-3-oxoandrosta-1, 4-dieno-17\beta-carbotioato. BR112015029530A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1881MU2013 2013-05-28
PCT/IN2014/000359 WO2014192027A1 (en) 2013-05-28 2014-05-28 Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy) but-2-ynyl] 6alpha, 9alpha-difluoro-17alpha-(furan-2-yl) carbonyloxy-11beta -hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta -carbothioate.

Publications (2)

Publication Number Publication Date
BR112015029530A2 BR112015029530A2 (pt) 2017-07-25
BR112015029530A8 true BR112015029530A8 (pt) 2019-12-17

Family

ID=51300796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015029530A BR112015029530A8 (pt) 2013-05-28 2014-05-28 métodos para tratamento de condições inflamatórias utilizando s-[4-(3-fluoro-3-metilbutiriloxi)but-2-inil] 6\alpha, 9\alpha-difluoro-17\alpha-(furan-2-il)carboniloxi-11\beta-hidroxi-16\alpha-metil-3-oxoandrosta-1, 4-dieno-17\beta-carbotioato.

Country Status (18)

Country Link
US (1) US9458187B2 (pt)
EP (1) EP3004133B1 (pt)
JP (1) JP6366696B2 (pt)
KR (1) KR20160030085A (pt)
CN (1) CN105431445A (pt)
AU (1) AU2014272640B2 (pt)
BR (1) BR112015029530A8 (pt)
CA (1) CA2912400A1 (pt)
EA (1) EA027831B9 (pt)
ES (1) ES2664019T3 (pt)
IL (1) IL242658A0 (pt)
MX (1) MX2015016283A (pt)
MY (1) MY179214A (pt)
PH (1) PH12015502652A1 (pt)
SG (1) SG11201509680TA (pt)
UA (1) UA117248C2 (pt)
WO (1) WO2014192027A1 (pt)
ZA (1) ZA201508640B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2912400A1 (en) 2013-05-28 2014-12-04 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6.alpha.,9.alpha.-difluoro-17.alpha.-(furan-2-yl)carbonyloxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxoandrosta-1,4-diene-17.beta.-carbothioate
CA2975363A1 (en) * 2015-01-31 2016-08-04 Jiten Ranchhodbhai Patel Crystalline forms of s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6.alpha.,9.alpha.-difluoro-17.alpha.-(furan-2-yl)carbonyloxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxoandrosta-1,4-diene-17.beta.-carbothioate
CN106279341A (zh) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 一种糠酸氟替卡松的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH24267A (en) 1980-02-15 1990-05-29 Glaxo Group Ltd Androstane carbothioates and pharmaceutical compositions containing the same
EP1534733A2 (en) 2002-06-20 2005-06-01 Sun Pharmaceuticals Industries Ltd. Convenient synthesis of s-fluoromethyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha- methyl-17alpha-propionyloxy-3-oxoandrosta-1, 4-diene-17beta-carbothioate
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
AR059216A1 (es) * 2006-01-27 2008-03-19 Sun Pharmaceutical Ind Ltd 11b-hidroxiandrosta-4-eno-3-onas
CA2912400A1 (en) 2013-05-28 2014-12-04 Sun Pharma Advanced Research Company Limited Methods for treatment of inflammatory conditions using s-[4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl]6.alpha.,9.alpha.-difluoro-17.alpha.-(furan-2-yl)carbonyloxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxoandrosta-1,4-diene-17.beta.-carbothioate

Also Published As

Publication number Publication date
KR20160030085A (ko) 2016-03-16
IL242658A0 (en) 2016-02-01
CN105431445A (zh) 2016-03-23
UA117248C2 (uk) 2018-07-10
EA201592283A1 (ru) 2016-04-29
JP6366696B2 (ja) 2018-08-01
SG11201509680TA (en) 2015-12-30
US20160102117A1 (en) 2016-04-14
MX2015016283A (es) 2016-03-11
EA027831B1 (ru) 2017-09-29
EA027831B9 (ru) 2017-12-29
MY179214A (en) 2020-11-02
EP3004133B1 (en) 2018-03-07
WO2014192027A1 (en) 2014-12-04
BR112015029530A2 (pt) 2017-07-25
ZA201508640B (en) 2017-09-27
AU2014272640A1 (en) 2015-11-26
EP3004133A1 (en) 2016-04-13
PH12015502652A1 (en) 2016-03-07
ES2664019T3 (es) 2018-04-18
JP2016520122A (ja) 2016-07-11
CA2912400A1 (en) 2014-12-04
AU2014272640B2 (en) 2018-04-05
US9458187B2 (en) 2016-10-04

Similar Documents

Publication Publication Date Title
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112019002275A2 (pt) inibidores aminopirimidina de ssaos
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
GT201600123A (es) Inhibidores de syk
EA201690669A8 (ru) Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
BR112016000975A8 (pt) esteróides neuroativos, composições os compreendendo e uso dos mesmos
BR112017009648A2 (pt) composto, métodos para tratamento de doenças alérgicas ou outras condições inflamatórias ou prevenção de doença, de rinite alérgica ou asma, composição, e, uso de um composto.
BR112018069533A2 (pt) tratamento de condições alérgicas oculares com ciclodextrinas
EA201690094A1 (ru) Ингибиторы syk
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
CR20160229A (es) Inhibidires de bromodominio
EA201591531A1 (ru) Ингибиторы аргининметилтрансферазы и их применения
UY35300A (es) Formulación de combinación de dos compuestos antivirales
BR112015017878A2 (pt) composto da fórmula estrutural ii, composto da fórmula estrutural iii, composição farmacêutica e método de tratamento de um distúrbio mediado por vmat2
BR112015032595A2 (pt) inibidores de ido
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
BR112021026668A2 (pt) Compostos heterocíclicos como inibidores de bet
BR112017017349A2 (pt) composto, composição, método para tratar um distúrbio
BR112015029462A2 (pt) Inibidores de quinase
BR112018011633A2 (pt) inibidores de aza-benzimidazol de pad4
IN2015DN00370A (pt)
BR112017022281A2 (pt) métodos para tratar câncer
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]